ATE324908T1 - Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems - Google Patents

Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems

Info

Publication number
ATE324908T1
ATE324908T1 AT00930402T AT00930402T ATE324908T1 AT E324908 T1 ATE324908 T1 AT E324908T1 AT 00930402 T AT00930402 T AT 00930402T AT 00930402 T AT00930402 T AT 00930402T AT E324908 T1 ATE324908 T1 AT E324908T1
Authority
AT
Austria
Prior art keywords
rubeola
antbody
nervous system
central nervous
system diseases
Prior art date
Application number
AT00930402T
Other languages
English (en)
Inventor
John Mcmichael
Allan D Lieberman
Original Assignee
Milkhaus Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Milkhaus Lab Inc filed Critical Milkhaus Lab Inc
Application granted granted Critical
Publication of ATE324908T1 publication Critical patent/ATE324908T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT00930402T 1999-09-14 2000-05-05 Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems ATE324908T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15383899P 1999-09-14 1999-09-14
US09/514,993 US6187309B1 (en) 1999-09-14 2000-02-29 Method for treatment of symptoms of central nervous system disorders

Publications (1)

Publication Number Publication Date
ATE324908T1 true ATE324908T1 (de) 2006-06-15

Family

ID=26850911

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00930402T ATE324908T1 (de) 1999-09-14 2000-05-05 Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems

Country Status (9)

Country Link
US (1) US6187309B1 (de)
EP (1) EP1212088B1 (de)
JP (1) JP3762891B2 (de)
AT (1) ATE324908T1 (de)
AU (1) AU781889B2 (de)
CA (1) CA2391808C (de)
DE (1) DE60027732T2 (de)
IL (2) IL148071A0 (de)
WO (1) WO2001019398A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6294171B2 (en) * 1999-09-14 2001-09-25 Milkhaus Laboratory, Inc. Methods for treating disease states comprising administration of low levels of antibodies
US6436401B1 (en) * 1999-09-14 2002-08-20 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with diabetes and diabetic neuropathy comprising administration of low levels of antibodies
US6713058B2 (en) 1999-09-14 2004-03-30 Milkhaus Laboratory, Inc. Methods for alleviating symptoms associated with neuropathic conditions comprising administration of low levels of antibodies
US6632429B1 (en) 1999-12-17 2003-10-14 Joan M. Fallon Methods for treating pervasive development disorders
US20070053895A1 (en) * 2000-08-14 2007-03-08 Fallon Joan M Method of treating and diagnosing parkinsons disease and related dysautonomic disorders
US8030002B2 (en) 2000-11-16 2011-10-04 Curemark Llc Methods for diagnosing pervasive development disorders, dysautonomia and other neurological conditions
MXPA04003156A (es) * 2001-10-04 2005-01-25 Protein Therapeutics Inc El uso de gammaglobulina para el tratamiento de enfermedades mediadas inmunes .
US20090011048A1 (en) * 2002-04-16 2009-01-08 Coleman Henry D Dietary Supplement For Promoting Removal Of Heavy Metals From The Body
EP1579357A4 (de) * 2002-11-22 2007-09-05 John D Bixler System und verfahren zur behandlung von autismus
US20060198838A1 (en) * 2004-09-28 2006-09-07 Fallon Joan M Combination enzyme for cystic fibrosis
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
US20070116695A1 (en) * 2005-09-21 2007-05-24 Fallon Joan M Pharmaceutical preparations for attention deficit disorder, attention deficit hyperactivity disorder and other associated disorders
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
SG177954A1 (en) * 2007-01-05 2012-02-28 Univ Zuerich Method of providing disease-specific binding molecules and targets
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
US8084025B2 (en) 2008-04-18 2011-12-27 Curemark Llc Method for the treatment of the symptoms of drug and alcohol addiction
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
WO2010002972A1 (en) * 2008-07-01 2010-01-07 Curemark, Llc Methods and compositions for the treatment of symptoms of neurological and mental health disorders
US10776453B2 (en) * 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
EP2949666B1 (de) 2008-12-19 2018-12-19 Biogen International Neuroscience GmbH Menschliche anti-alpha-synuclein-antikörper
EP2947100B1 (de) 2009-01-06 2019-05-08 Galenagen, LLC Orale Zusammensetzungen zur Behandlung oder Prävention von Infektionen durch E. Coli
BRPI1007378A2 (pt) 2009-01-06 2020-08-18 Curemark Llc composições e métodos para o tratamento ou prevenção de infecções por staphylococcus aureus e para a erradicação ou redução de staphylococcus aureus sobre superfícies.
US9056050B2 (en) * 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
WO2011050135A1 (en) 2009-10-21 2011-04-28 Curemark Llc Methods and compositions for the prevention and treatment of influenza
HUE050873T2 (hu) 2011-04-21 2021-01-28 Curemark Llc Vegyületek neuropszichiátriai rendellenességek kezelésére
DK2723379T3 (en) 2011-06-23 2018-10-15 Biogen Int Neuroscience Gmbh ANTI-ALPHA SYNUCLEIN BINDING MOLECULES
WO2013139861A1 (en) 2012-03-20 2013-09-26 Luc Montagnier Methods and pharmaceutical compositions of the treatment of autistic syndrome disorders
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
MA49947B1 (fr) 2017-08-22 2023-03-31 Biogen Ma Inc Compositions pharmaceutiques contenant des anticorps anti-bêta-amyloïdes
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3408M (fr) * 1964-03-25 1965-07-05 Michel Plissier Immunoglobulines d'origine animale, antivirus de la rougeole, seules ou associées a d'autres immunoglobulines ou médicaments.
JPS56113713A (en) * 1980-02-14 1981-09-07 Chemo Sero Therapeut Res Inst Preparation of immunoglobulin with high content of monomer
US4521405A (en) * 1982-05-17 1985-06-04 John McMichael Methods and materials for treatment of disease states involving immunological factors
JPS59157017A (ja) * 1983-02-25 1984-09-06 Green Cross Corp:The 静脈投与用γ−グロブリン製剤

Also Published As

Publication number Publication date
CA2391808C (en) 2008-10-28
DE60027732D1 (de) 2006-06-08
DE60027732T2 (de) 2006-09-14
WO2001019398A1 (en) 2001-03-22
JP2003509382A (ja) 2003-03-11
IL148071A0 (en) 2002-09-12
EP1212088A4 (de) 2004-08-18
AU781889B2 (en) 2005-06-23
CA2391808A1 (en) 2001-03-22
EP1212088B1 (de) 2006-05-03
AU4822800A (en) 2001-04-17
US6187309B1 (en) 2001-02-13
JP3762891B2 (ja) 2006-04-05
EP1212088A1 (de) 2002-06-12
IL148071A (en) 2008-07-08

Similar Documents

Publication Publication Date Title
ATE324908T1 (de) Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE241358T1 (de) Verwendung von cholinesterasehemmer zur behandlung von konzentrationsstörungen
DE69616376T2 (de) Verwendung von Tiagabin zur Behandlung von Schlafstörungen
ATE348808T1 (de) Azacyclische verbindungen zur verwendung in der behandlung von mit serotonin verwandten krankheiten
DE69634900D1 (de) Proteintyrosine-kinaseinhibitoren zur behandlung der osteoarthritis
ATE307592T1 (de) Epiallopregnanolon zur behandlung von krankheiten des cns
ATE329588T1 (de) Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen
DE69929464D1 (de) Zyklische polyamine zur behandlung der thrombozytopenie
ATE331527T1 (de) Verfahren zur behandlung von brustdrüsenerkrankungen
ATE428413T1 (de) Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
ATE304855T1 (de) Verwendung von olanzapin zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
DE60008753D1 (de) Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
DE69918972D1 (de) Verwendung von nmda-antagonisten und/oder natriumkanalantagonisten zur behandlung von entzündlichen erkrankungen
ATE281841T1 (de) Verfahren zur herstellung von mikania extrakten enthaltend mikanolide und dihydromikanolide und verwendung in der behandlung proliferativer erkrankungen
DE69619187T2 (de) Verfahren zur behandlung von motorischen defiziten
DE60111620D1 (de) Aktiviertes protein c zur behandlung von pankreatitis
ATE248596T1 (de) Verwendung von nicergoline zur behandlung der spastizität
DE69736180D1 (de) Behandlung von manischen erkrankungen
DE60004473D1 (de) Verwendung von gaba-b rezeptor liganden zur herstellungen von medikamenten zur behandlung von neurodegenerativen erkrankungen
ATE291434T1 (de) Verwendung von angiotensin zur behandlung von krebsmetastasierung
DE60128084D1 (de) Verwendung von inaktives cln2 proenzym zur behandlung von lincl
DE69915849D1 (de) Verwendung von gnrh analogen zur behandlung von schizophrenie
DE59609219D1 (de) Verwendung von 1-hydroxy-2-pyridonen zur behandlung von schwer therapierbaren schleimhauterkrankungen
ATE311190T1 (de) Verwendung von trizyklischen antidepressiva zur behandlung von kopfschmerzen
DE10193322D2 (de) Verwendung von Protonenpumpen-Hemmern zur Behandlung von Erkrankungen des Bewegungsapparates

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties